Hosted on MSN

Q&A: Two decades of research lead to treatment for rare, painful skin condition

Patients with severe dystrophic epidermolysis bullosa, or EB, have skin so fragile, the slightest touch can lead to blistering and, eventually, large, open wounds that never heal, causing immense pain ...
Hosted on MSN

Phase III trial shows gene therapy skin grafts help heal chronic wounds in blistering skin disease

Skin grafts genetically engineered from a patient's own cells can heal persistent wounds in people with an extremely painful dermatologic disease, a Stanford Medicine-led clinical trial has shown. The ...
Morningstar

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa

- RDEB is a lifelong debilitating, blistering skin disease associated with large and painful wounds that often remain open for years and cause significant clinical burden, including pain, itch, and ...
Nasdaq

Abeona Therapeutics Announces Publication of Positive Phase 3 VIITAL Study Results for ZEVASKYN™ in Treatment of Wounds from Recessive Dystrophic Epidermolysis Bullosa (RDEB)

ZEVASKYN™ shows significant wound healing and pain reduction in RDEB patients, marking a breakthrough treatment option approved by the FDA. ZEVASKYN is the first and only autologous cell-based gene ...
Nasdaq

Abeona Therapeutics Receives FDA Approval for ZEVASKYN™ as First Gene Therapy for Wounds in Recessive Dystrophic Epidermolysis Bullosa Patients

Abeona Therapeutics has received FDA approval for ZEVASKYN, the first autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a ...